Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cytomegalovirus (HHV-5) Infections-Pipeline Review, H1 2015

Cytomegalovirus (HHV-5) Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cytomegalovirus (HHV-5) Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections-Pipeline Review, H1 2015', provides an overview of the Cytomegalovirus (HHV-5) Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cytomegalovirus (HHV-5) Infections Overview 9

Therapeutics Development 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections-Overview 10

Pipeline Products for Cytomegalovirus (HHV-5) Infections-Comparative Analysis 11

Cytomegalovirus (HHV-5) Infections-Therapeutics under Development by Companies 12

Cytomegalovirus (HHV-5) Infections-Therapeutics under Investigation by Universities/Institutes 16

Cytomegalovirus (HHV-5) Infections-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Cytomegalovirus (HHV-5) Infections-Products under Development by Companies 22

Cytomegalovirus (HHV-5) Infections-Products under Investigation by Universities/Institutes 25

Cytomegalovirus (HHV-5) Infections-Companies Involved in Therapeutics Development 26

3-V Biosciences, Inc. 26

AIMM Therapeutics B.V. 27

AlphaVax, Inc. 28

Altor BioScience Corporation 29

Applied Immune Technologies Ltd 30

Astellas Pharma Inc. 31

BioApex, s.r.o. 32

Bionor Pharma ASA 33

Biotest AG 34

CAP-CMV GmbH 35

Cell Medica Limited 36

Chimerix, Inc. 37

GlaxoSmithKline plc 38

Hookipa Biotech AG 39

Humabs BioMed SA 40

INAGEN ApS 41

iQur Ltd. 42

Kadmon Corporation, LLC 43

Lead Discovery Center GmbH 44

Merck & Co., Inc. 45

Microbiotix, Inc. 46

Novartis AG 47

Pfizer Inc. 48

Phoenix Biotechnology, Inc. 49

Spider Biotech 50

Trellis Bioscience, Inc. 51

Vakzine Projekt Management GmbH 52

VBI Vaccines Inc. 53

Vical Incorporated 54

Cytomegalovirus (HHV-5) Infections-Therapeutics Assessment 55

Assessment by Monotherapy Products 55

Assessment by Target 56

Assessment by Mechanism of Action 58

Assessment by Route of Administration 60

Assessment by Molecule Type 62

Drug Profiles 64

AL-18-Drug Profile 64

Antibody to Inhibit HLA-A2 for Cytomegalovirus Infections-Drug Profile 65

Antiviral TCR-Ck-Drug Profile 66

Antiviral TCR-Ig-Drug Profile 67

ASP-0113-Drug Profile 68

AVX-601-Drug Profile 69

BA-368-Drug Profile 71

brincidofovir-Drug Profile 72

BT-084-Drug Profile 74

CAPCMV-001-Drug Profile 75

Cell Therapy 3 For CMV-Drug Profile 76

Cell Therapy for CMV Infections-Drug Profile 77

Cell Therapy for Cytomegalovirus (HHV-5) Infections-Drug Profile 78

Cell Therapy for Cytomegalovirus Infections-Drug Profile 79

Cell Therapy for Cytomegalovirus Infections-Drug Profile 80

Cell Therapy for Cytomegalovirus Infections and GBM-Drug Profile 81

Cell Therapy for Infectious Disease-Drug Profile 82

Cell Therapy for Infectious Diseases-Drug Profile 83

Cell Therapy to Target PP65 for Cytomegalovirus Infections-Drug Profile 84

Cell Therapy to Target PP65 for Cytomegalovirus Infections-Drug Profile 86

CMX-669-Drug Profile 87

CSJ-148-Drug Profile 88

CyMVectin-Drug Profile 89

cytomegalovirus (virus like particle) vaccine-Drug Profile 90

cytomegalovirus vaccine-Drug Profile 91

cytomegalovirus vaccine-Drug Profile 92

Cytomegalovirus vaccine-Drug Profile 93

cytomegalovirus vaccine-Drug Profile 94

cytomegalovirus vaccine 1-Drug Profile 95

Cytovir-CMV-Drug Profile 97

Dendritic Cell Therapy for Oncology and Infectious Disease-Drug Profile 99

Dendritic Cell Therapyto Target CMV Antigen for Cytomegalovirus Infections-Drug Profile 100

Drug for Cytomegalovirus-Drug Profile 101

filociclovir-Drug Profile 102

Gene Therapy for Cytomegalovirus Infections-Drug Profile 104

HB-101-Drug Profile 105

LDC-4297-Drug Profile 106

letermovir-Drug Profile 107

maribavir-Drug Profile 108

MBX-2168-Drug Profile 110

Monoclonal Antibody for Cytomegalovirus Infections-Drug Profile 111

Monoclonal Antibody for HCMV Infections-Drug Profile 112

Peptides to Inhibit Heparan Sulfate for HHV-5 Infections-Drug Profile 113

Protein For Cytomegalovirus Infections-Drug Profile 114

RBT-301-Drug Profile 115

Recombinant Peptide for Infectious Diseases-Drug Profile 116

RKP-00156-Drug Profile 117

SB-105A10-Drug Profile 118

Small Molecule 1 for Human Cytomegalovirus Infection-Drug Profile 120

Small Molecule 2 for Human Cytomegalovirus Infection-Drug Profile 121

Small Molecule 3 for Human Cytomegalovirus Infection-Drug Profile 122

Small Molecules for CMV Infections-Drug Profile 123

Small Molecules for Viral Infections-Drug Profile 124

Small Molecules to Activate Sirtuin for Viral Infections-Drug Profile 125

Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections-Drug Profile 126

Small Molecules to Inhibit Fatty Acid Synthase for Viral Infections-Drug Profile 127

TRL-345-Drug Profile 128

V-160-Drug Profile 129

Vacc-CMV-Drug Profile 130

VBI-1501A-Drug Profile 131

Viralym-C-Drug Profile 132

VPM-2001-Drug Profile 133

Cytomegalovirus (HHV-5) Infections-Recent Pipeline Updates 134

Cytomegalovirus (HHV-5) Infections-Dormant Projects 152

Cytomegalovirus (HHV-5) Infections-Discontinued Products 156

Cytomegalovirus (HHV-5) Infections-Product Development Milestones 157

Featured News & Press Releases 157

Appendix 163

Methodology 163

Coverage 163

Secondary Research 163

Primary Research 163

Expert Panel Validation 163

Contact Us 163

Disclaimer 164

List of Tables

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2015 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 21

Comparative Analysis by Late Stage Development, H1 2015 22

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Development, H1 2015 24

Comparative Analysis by Unknown Stage Development, H1 2015 25

Products under Development by Companies, H1 2015 26

Products under Development by Companies, H1 2015 (Contd..1) 27

Products under Development by Companies, H1 2015 (Contd..2) 28

Products under Investigation by Universities/Institutes, H1 2015 29

Cytomegalovirus (HHV-5) Infections-Pipeline by 3-V Biosciences, Inc., H1 2015 30

Cytomegalovirus (HHV-5) Infections-Pipeline by AIMM Therapeutics B.V., H1 2015 31

Cytomegalovirus (HHV-5) Infections-Pipeline by AlphaVax, Inc., H1 2015 32

Cytomegalovirus (HHV-5) Infections-Pipeline by Altor BioScience Corporation, H1 2015 33

Cytomegalovirus (HHV-5) Infections-Pipeline by Applied Immune Technologies Ltd, H1 2015 34

Cytomegalovirus (HHV-5) Infections-Pipeline by Astellas Pharma Inc., H1 2015 35

Cytomegalovirus (HHV-5) Infections-Pipeline by BioApex, s.r.o., H1 2015 36

Cytomegalovirus (HHV-5) Infections-Pipeline by Bionor Pharma ASA, H1 2015 37

Cytomegalovirus (HHV-5) Infections-Pipeline by Biotest AG, H1 2015 38

Cytomegalovirus (HHV-5) Infections-Pipeline by CAP-CMV GmbH, H1 2015 39

Cytomegalovirus (HHV-5) Infections-Pipeline by Cell Medica Limited, H1 2015 40

Cytomegalovirus (HHV-5) Infections-Pipeline by Chimerix, Inc., H1 2015 41

Cytomegalovirus (HHV-5) Infections-Pipeline by GlaxoSmithKline plc, H1 2015 42

Cytomegalovirus (HHV-5) Infections-Pipeline by Hookipa Biotech AG, H1 2015 43

Cytomegalovirus (HHV-5) Infections-Pipeline by Humabs BioMed SA, H1 2015 44

Cytomegalovirus (HHV-5) Infections-Pipeline by INAGEN ApS, H1 2015 45

Cytomegalovirus (HHV-5) Infections-Pipeline by iQur Ltd., H1 2015 46

Cytomegalovirus (HHV-5) Infections-Pipeline by Kadmon Corporation, LLC, H1 2015 47

Cytomegalovirus (HHV-5) Infections-Pipeline by Lead Discovery Center GmbH, H1 2015 48

Cytomegalovirus (HHV-5) Infections-Pipeline by Merck & Co., Inc., H1 2015 49

Cytomegalovirus (HHV-5) Infections-Pipeline by Microbiotix, Inc., H1 2015 50

Cytomegalovirus (HHV-5) Infections-Pipeline by Novartis AG, H1 2015 51

Cytomegalovirus (HHV-5) Infections-Pipeline by Pfizer Inc., H1 2015 52

Cytomegalovirus (HHV-5) Infections-Pipeline by Phoenix Biotechnology, Inc., H1 2015 53

Cytomegalovirus (HHV-5) Infections-Pipeline by Spider Biotech, H1 2015 54

Cytomegalovirus (HHV-5) Infections-Pipeline by Trellis Bioscience, Inc., H1 2015 55

Cytomegalovirus (HHV-5) Infections-Pipeline by Vakzine Projekt Management GmbH, H1 2015 56

Cytomegalovirus (HHV-5) Infections-Pipeline by VBI Vaccines Inc., H1 2015 57

Cytomegalovirus (HHV-5) Infections-Pipeline by Vical Incorporated, H1 2015 58

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Stage and Target, H1 2015 61

Number of Products by Stage and Mechanism of Action, H1 2015 63

Number of Products by Stage and Route of Administration, H1 2015 65

Number of Products by Stage and Molecule Type, H1 2015 67

Cytomegalovirus (HHV-5) Infections Therapeutics-Recent Pipeline Updates, H1 2015 138

Cytomegalovirus (HHV-5) Infections-Dormant Projects, H1 2015 156

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..1), H1 2015 157

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..2), H1 2015 158

Cytomegalovirus (HHV-5) Infections-Dormant Projects (Contd..3), H1 2015 159

Cytomegalovirus (HHV-5) Infections-Discontinued Products, H1 2015 160

List of Figures

Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2015 14

Number of Products under Development for Cytomegalovirus (HHV-5) Infections-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Clinical Stage Development, H1 2015 23

Comparative Analysis by Early Stage Products, H1 2015 24

Assessment by Monotherapy Products, H1 2015 59

Number of Products by Top 10 Targets, H1 2015 60

Number of Products by Stage and Top 10 Targets, H1 2015 60

Number of Products by Top 10 Mechanism of Actions, H1 2015 62

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 63

Number of Products by Top 10 Routes of Administration, H1 2015 64

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 65

Number of Products by Top 10 Molecule Types, H1 2015 66

Number of Products by Stage and Top 10 Molecule Types, H1 2015 67

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

AIMM Therapeutics B.V.

AlphaVax, Inc.

Altor BioScience Corporation

Applied Immune Technologies Ltd

Astellas Pharma Inc.

BioApex, s.r.o.

Bionor Pharma ASA

Biotest AG

CAP-CMV GmbH

Cell Medica Limited

Chimerix, Inc.

GlaxoSmithKline plc

Hookipa Biotech AG

Humabs BioMed SA

INAGEN ApS

iQur Ltd.

Kadmon Corporation, LLC

Lead Discovery Center GmbH

Merck & Co., Inc.

Microbiotix, Inc.

Novartis AG

Pfizer Inc.

Phoenix Biotechnology, Inc.

Spider Biotech

Trellis Bioscience, Inc.

Vakzine Projekt Management GmbH

VBI Vaccines Inc.

Vical Incorporated

Cytomegalovirus (HHV-5) Infections Therapeutic Products under Development, Key Players in Cytomegalovirus (HHV-5) Infections Therapeutics, Cytomegalovirus (HHV-5) Infections Pipeline Overview, Cytomegalovirus (HHV-5) Infections Pipeline, Cytomegalovirus (HHV-5) Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com